EUVIMEDEUVIMED entdecken
KommentarOpen Access

Case Commentary: Dual β-lactam as part of regimen to treat Mycobacterium abscessus lung disease

Christopher K Lippincott, Gyanu Lamichhane iD

Antimicrobial Agents and Chemotherapy · 2024

DOI: 10.1128/aac.00585-24 ↗

Kurz gefasst

Kommentar in der Zeitschrift Antimicrobial Agents and Chemotherapy, 2024. Verfasst von Christopher K Lippincott und 1 weiteren Autor:innen. Beteiligte Einrichtung: Division of Infectious Diseases, Department of Medicine, School of Medicine, Johns Hopkins University, Baltimore, Maryland, USA. Hauptthemen laut MEDLINE: Mycobacterium abscessus, Mycobacterium Infections, Nontuberculous, Anti-Bacterial Agents, beta-Lactams. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Individuals with compromised lung function and immunity are susceptible to developing chronic Mycobacterium abscessus infection. Current treatment recommendations typically involve using one β-lactam antibiotic in combination with non-β-lactam antibiotics. However, a recent case study (B. Becken, K. M. Dousa, J. L. Johnson, S. M. Holland, and R. A. Bonomo, Antimicrob Agents Chemother 68:e00319-24, 2024, https://doi.org/10.1128/aac.00319-24 ) demonstrated successful treatment of chronic M. abscessus lung disease in a child using two β-lactam antibiotics simultaneously. This commentary reviews the emerging evidence and outstanding questions regarding dual β-lactam therapy for M. abscessus infections.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Mycobacterium abscessusMycobacterium Infections, NontuberculousAnti-Bacterial Agentsbeta-LactamsLung DiseasesHumansDrug Therapy, CombinationChildCase Reports as Topic

Stichwörter der Autor:innen

Mycobacterium abscessuscefdinirdual beta-lactamimipenem

Substanzen

Anti-Bacterial Agentsbeta-Lactams

Autor:innen und Institutionen

  • Division of Infectious Diseases, Department of Medicine, School of Medicine, Johns Hopkins University, Baltimore, Maryland, USA.
  • Center for Nontuberculous Mycobacteria and Bronchiectasis, School of Medicine, Johns Hopkins University, Baltimore, Maryland, USA.

ORCID-Profile: Gyanu Lamichhane

Zitieren

APA

Lippincott, C. K., & Lamichhane, G. (2024). Case Commentary: Dual β-lactam as part of regimen to treat Mycobacterium abscessus lung disease. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.00585-24

Vancouver

Lippincott CK, Lamichhane G. Case Commentary: Dual β-lactam as part of regimen to treat Mycobacterium abscessus lung disease. Antimicrobial Agents and Chemotherapy. 2024. doi:10.1128/aac.00585-24

BibTeX
@article{Lippincott2024,
  author = {Lippincott, Christopher K and Lamichhane, Gyanu},
  title = {Case Commentary: Dual β-lactam as part of regimen to treat Mycobacterium abscessus lung disease},
  journal = {Antimicrobial Agents and Chemotherapy},
  year = {2024},
  doi = {10.1128/aac.00585-24}
}
Kostenlos starten →